<DOC>
	<DOCNO>NCT00371943</DOCNO>
	<brief_summary>Both medication beta-blockers isosorbide-5-mononitrate endoscopic variceal ligation proven plausible prevention variceal rebleeding . However , relative efficacy safety combine treatment prevent rebleeding remains unresolved .</brief_summary>
	<brief_title>EVL Plus Drug Prevent Variceal Rebleeding</brief_title>
	<detailed_description>Bleeding esophageal varix severe complication portal hypertension . After initial control acute variceal bleeding , patient still carry high risk rebleeding . Of rebleed , 20 % -35 % mortality ( 1 ) . Therefore , preventive procedure require patient survive episode acute variceal bleeding . In recent year , endoscopic variceal ligation ( EVL ) replace endoscopic injection sclerotherapy ( EIS ) endoscopic treatment choice management bleed esophageal varix ( 2-3 ) . On hand , nonselective beta blocker well document effective reduce variceal rebleeding ( 4-5 ) . The addition isosorbide-5-mononitrate ( ISMN ) show even effective propranolol alone reduction portal pressure prevention variceal rebleeding ( 6 ) . Some study show combination nadolol ISMN effective EIS EVL reduction variceal rebleeding ( 7-8 ) . It still unknown whether EVL combine nadolol ISMN superior nadolol ISMN prevention variceal rebleeding . This study undertaken compare effectiveness complication ligation plus nadolol isosorbide mononitrate vs. nadolol plus isosorbide mononitrate prevention variceal rebleeding .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<criteria>1 . Acute bleed esophageal varix ( define ) ; 2. etiology portal hypertension cirrhosis ; 3. age 20 75 year old . The diagnosis cirrhosis base pathology , clinical , biochemical , sonographic compute tomographic finding . Acute esophageal variceal bleeding define blood directly see endoscopy issue esophageal varix , patient present red color sign esophageal varix blood esophagus stomach potential site bleeding identify . 1. association hepatocellular carcinoma malignancy , 2. association cerebral vascular accident , uremia , sepsis debilitate disease , 3. history gastric variceal bleeding , 4. receive beta blocker within one month prior entry , 5. history contraindication use beta blocker , asthma , heart failure , atrioventricular block , bradycardia ( pulse rate &lt; 55/min ) arterial hypotension ( systolic blood pressure &lt; 90 mmHg ) . 6. history prior shunt operation , TIPS ( transjugular intrahepatic portosystemic stent shunt ) , EIS EVL , 7. deep jaundice ( serum bilirubin &gt; 10mg/dl ) , 8. encephalopathy great stage II , 9. failure control index variceal bleeding , 10. death within 24 hour admission , 11. refuse participate trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>variceal bleeding , band ligation , beta-blocker</keyword>
	<keyword>history esophageal variceal bleeding</keyword>
</DOC>